112 related articles for article (PubMed ID: 29498403)
1. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Sugiura F; Inoue K; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of OCV-C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer.
Taniguchi H; Iwasa S; Yamazaki K; Yoshino T; Kiryu C; Naka Y; Liew EL; Sakata Y
Cancer Sci; 2017 May; 108(5):1013-1021. PubMed ID: 28266765
[TBL] [Abstract][Full Text] [Related]
10. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report.
Yasuda S; Tsuchiya I; Okada K; Tanaka A; Suzuki T; Sadahiro S; Takeda K; Yamamoto S; Nakui M
Tokai J Exp Clin Med; 2012 Jul; 37(2):57-61. PubMed ID: 22763829
[TBL] [Abstract][Full Text] [Related]
11. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.
Fujiwara Y; Okada K; Omori T; Sugimura K; Miyata H; Ohue M; Kobayashi S; Takahashi H; Nakano H; Mochizuki C; Shimizu K; Yano M; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2017 May; 50(5):1655-1662. PubMed ID: 28393243
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer.
Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M
Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial.
Shimizu Y; Yoshikawa T; Kojima T; Shoda K; Nosaka K; Mizuno S; Wada S; Fujimoto Y; Sasada T; Kohashi K; Bando H; Endo I; Nakatsura T
Cancer Sci; 2019 Oct; 110(10):3049-3060. PubMed ID: 31390678
[TBL] [Abstract][Full Text] [Related]
14. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
[TBL] [Abstract][Full Text] [Related]
16. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.
Suda T; Tsunoda T; Daigo Y; Nakamura Y; Tahara H
Cancer Sci; 2007 Nov; 98(11):1803-8. PubMed ID: 17784873
[TBL] [Abstract][Full Text] [Related]
17. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
Hazama S; Takenouchi H; Tsunedomi R; Iida M; Suzuki N; Iizuka N; Inoue Y; Sakamoto K; Nakao M; Shindo Y; Kanekiyo S; Tokumitsu Y; Yoshimura K; Maeda N; Maeda K; Maeda Y; Matsui H; Yoshino S; Nakamura Y; Fujita Y; Hamamoto Y; Okamoto M; Fujita T; Kawakami Y; Oka M
Anticancer Res; 2014 Aug; 34(8):4201-5. PubMed ID: 25075047
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.
Higashihara Y; Kato J; Nagahara A; Izumi K; Konishi M; Kodani T; Serizawa N; Osada T; Watanabe S
Int J Oncol; 2014 Mar; 44(3):662-8. PubMed ID: 24398900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
